IJCP Editorial Team
US FDA Approves Regeneron’s Cholesterol Drug in Children
This Wednesday, Regeneron Pharmaceuticals Inc announced that the United States Food and Drug Administration (US FDA) has approved its drug Evkeeza for use in children with homozygous familial hypercholesterolemia (HoFH), between 5-11 years of age.
HoFH – an inherited condition, is a rare disorder that causes high low-density lipoprotein (LDL) cholesterol levels and predisposes to premature cardiovascular diseases. In 2021, this drug gained approval as an additional treatment with other lipid-lowering therapies for children with HoFH, aged 12 years and above.
IJCP Editorial Team
Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.
More FAQs by IJCP Editorial Team
Recent FAQs
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please login to comment on this article